Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis

Aims: Currently, there are many approaches available for neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer that improve therapeutic efficacy but are also controversial. We conducted a two-step Bayesian network meta-analysis (NMA) to compare odds ratios (O...

Full description

Bibliographic Details
Main Authors:	Jie Zhang, Yushuai Yu, Yuxiang Lin, Shaohong Kang, Xinyin Lv, Yushan Liu, Jielong Lin, Jun Wang, Chuangui Song
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-04-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359211006948

Similar Items

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
by: J. Zhang, et al.
Published: (2021-04-01)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
by: Chen ZL, et al.
Published: (2016-05-01)

Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis
by: Di Wu, et al.
Published: (2019-01-01)

Efficacy and safety of neoadjuvant therapy for Triple-Negative Breast Cancer (TNBC): a Bayesian network meta-analysis
by: Y. Yu, et al.
Published: (2021-04-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: Yan H, et al.
Published: (2020-12-01)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
by: Wei Zhang, et al.
Published: (2017-01-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
by: Márcio Debiasi, et al.
Published: (2018-05-01)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01)

Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
by: Ma W, et al.
Published: (2019-01-01)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
by: Hee Jeong Kim, et al.
Published: (2020-05-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
by: Chaokun Wang MS, et al.
Published: (2020-09-01)

The efficacy and safety of Tyrosine kinase inhibitors in HER-2 positive breast cancer with brain metastases: a systematic review and meta analysis
by: Y. Yu, et al.
Published: (2021-04-01)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
by: Claudia Omarini, et al.
Published: (2020-09-01)

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
by: S. Guiu, et al.
Published: (2013-01-01)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
by: Qiuyan Yu, et al.
Published: (2015-01-01)

Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
by: Ma B, et al.
Published: (2016-02-01)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
by: Guoshuang Shen, et al.
Published: (2021-07-01)

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
by: Nadia Hussain, et al.
Published: (2018-01-01)

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
by: Susanne Crocamo, et al.
Published: (2019-05-01)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
by: Yifan Xie, et al.
Published: (2021-06-01)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
by: G. Griguolo, et al.
Published: (2021-03-01)

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: Tamera J. Lillemoe, et al.
Published: (2021-01-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Correlation of immune infiltration with clinical outcomes in breast cancer patients: The 25‐gene prognostic signatures model
by: Yushan Liu, et al.
Published: (2021-03-01)

Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis
by: Feng F, et al.
Published: (2019-01-01)

The efficacy and safety of the targeted drug combined with adriamycin liposome solution for HER-2-positive breast cancer
by: Zi-Ping Zhou, et al.
Published: (2017-05-01)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
by: de Torraza Idalmis, et al.
Published: (2007-02-01)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
by: Nadia Harbeck
Published: (2018-07-01)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
by: Ricciardi GR, et al.
Published: (2016-07-01)

Effect of Herceptin combined with paclitaxel neoadjuvant chemotherapy on the proliferation viability of HER-2 positive breast cancer cell
by: Min He, et al.
Published: (2018-09-01)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
by: Ho Hyun Ryu, et al.
Published: (2021-05-01)

Impact of Postoperative Radiotherapy on Survival of Patients With de novo Stage IV Breast Cancer: A Population-Based Study From the SEER Database
by: Jie Zhang, et al.
Published: (2021-03-01)